Cartalax Research: Cartilage Bioregulator and Chondrocyte Biology

Cartalax (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide bioregulator derived from cartilage tissue, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as part of his systematic tissue-specific peptide bioregulator programme. Sharing the Ala-Glu-Asp core sequence with pineal Epithalon (Ala-Glu-Asp-Gly), Cartalax targets musculoskeletal and cartilage biology through the proposed epigenetic bioregulator mechanism.

Structural Context

Cartalax (Ala-Glu-Asp-Leu) differs from Epithalon (Ala-Glu-Asp-Gly) only at the C-terminal position — leucine versus glycine. This minimal structural difference is proposed in Khavinson's bioregulator framework to confer tissue-targeting specificity: the Ala-Glu-Asp core provides the shared epigenetic pharmacophore, while the C-terminal residue directs the bioregulator toward specific tissue chromatin. For Cartalax, leucine at position 4 is proposed to direct activity toward cartilage and connective tissue gene regulatory elements, while glycine at position 4 in Epithalon directs activity toward pineal tissue.

This one-residue difference makes Cartalax and Epithalon ideal research pair for investigating the tissue-specificity hypothesis of Khavinson bioregulators. Running both compounds in parallel in chondrocyte versus pinealocyte cell models at matched molar concentrations provides direct data on whether the C-terminal residue determines tissue-specific gene regulatory effects as proposed — or whether the Ala-Glu-Asp core produces similar effects regardless of C-terminal identity.

Chondrocyte Biology and Osteoarthritis Research

Primary chondrocyte isolation: Articular cartilage from the femoral condyles of bovine knee joints (obtained from abattoir) provides abundant primary chondrocytes for research. Mince cartilage, wash three times in PBS, then digest sequentially with Pronase (0.1%, 37°C, 1 hour) followed by collagenase type II (0.2%, 37°C, 12-16 hours) with gentle agitation. Filter through 70µm cell strainer. Wash cells and plate at 100,000 cells/cm2 in DMEM + 10% FBS + 50µg/mL ascorbate.

Inflammatory challenge model: Add IL-1beta (10ng/mL) to chondrocyte cultures for 24 hours to establish the catabolic OA phenotype. Then treat with Cartalax (1nM-10µM) for 48-72 hours while maintaining IL-1beta. Measure: COL2A1 (type II collagen gene) and ACAN (aggrecan gene) by RT-PCR for anabolic matrix synthesis; MMP-13 (collagenase-3) and ADAMTS-5 (aggrecanase-2) by RT-PCR and activity assay for catabolic enzyme suppression; SOX9 (master chondrocyte transcription factor) by Western blot; and IL-6, COX-2 as inflammatory markers.

Human osteoarthritic chondrocytes: Cartilage from total knee replacement surgery (with appropriate ethics approval and patient consent) provides OA chondrocytes that already exhibit the disease phenotype without exogenous IL-1beta stimulation. OA chondrocytes show elevated MMP-13, reduced COL2A1 and ACAN, elevated COX-2 and iNOS — a baseline catabolic phenotype that makes them a more clinically relevant model than normal chondrocytes with exogenous inflammatory challenge.

3D Cartilage Research Models

Two-dimensional chondrocyte monolayer culture does not maintain the rounded chondrocyte morphology or the high-proteoglycan environment of native cartilage. Three-dimensional culture systems better recapitulate cartilage biology and provide more predictive data.

Agarose encapsulation: Dissolve low-melting-point agarose at 4% w/v in PBS, cool to 37°C. Mix 1:1 with chondrocyte suspension at 40×10^6 cells/mL (final: 2% agarose, 20×10^6 cells/mL). Cast in 5mm diameter cylindrical moulds, allow gelation at room temperature. Transfer to culture medium with Cartalax supplementation. Incubate 21-42 days with medium changes every 2-3 days. At endpoint: hydroxyproline assay (total collagen content), dimethylmethylene blue (DMMB) colorimetric assay (glycosaminoglycan content), histology (Safranin-O/Fast Green, type II collagen IHC), and biomechanical testing (confined compression or dynamic mechanical analysis).

Fibrin hydrogel: Mix fibrinogen (20mg/mL in TBS) with chondrocytes, then add thrombin (2 U/mL) to initiate gelation. Culture in chondrogenic medium (DMEM-HG, 10ng/mL TGF-beta3, 100nM dexamethasone, 50µg/mL ascorbate, 40µg/mL L-proline) with and without Cartalax supplementation. TGF-beta3 at sub-maximal concentrations allows detection of Cartalax-mediated potentiation.

Key Published Research

• Khavinson VKh, et al. "Peptide bioregulators of tissue-specific functions." Saint Petersburg Institute of Bioregulation and Gerontology, 2003.
• Khavinson V, et al. "Short peptides stimulate genome expression." Advances in Gerontology, 2013.
• Anisimov VN, Khavinson VKh. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010. PMID: 20490741

View Cartalax →

For laboratory and analytical research purposes only. Not for human or veterinary use.

Cartalax and Tendon Biology

Connective tissue biology extends beyond articular cartilage to tendons and ligaments — tissues that share with cartilage the relative avascularity, high collagen content, and poor intrinsic repair capacity that make them challenging for regenerative research. Cartalax's derivation from connective tissue and its proposed effects on collagen synthesis make it relevant to tendon biology research as well as cartilage.

Tenocyte culture (primary tendon-derived cells isolated from rat Achilles tendons by collagenase digestion) provides a relevant research model. Tenocytes express collagen type I (90% of tendon collagen), collagen type III, tenascin-C, and decorin as their primary matrix components. Treat tenocyte cultures with Cartalax (1nM-10µM) for 72 hours. Measure: COL1A1 and COL3A1 mRNA by RT-PCR (type I and type III collagen synthesis); tenascin-C expression by Western blot; and total collagen content by Sirius Red staining of cell layer at assay endpoint. Compare with ascorbic acid (50µg/mL, essential cofactor for collagen hydroxylation) and TGF-beta1 (1ng/mL, a primary tendon repair growth factor) as reference standards.

Cartalax and Intervertebral Disc Research

Intervertebral disc degeneration — characterised by nucleus pulposus (NP) cell death, reduced proteoglycan synthesis, and progressive disc height loss — represents a major source of chronic low back pain and shares the avascular connective tissue environment with articular cartilage. NP cells express aggrecan and type II collagen (shared with chondrocytes) alongside the NP-specific marker T-brachyury, making them relevant targets for Cartalax research.

Primary rat or bovine NP cell isolation: dissect nucleus pulposus from intervertebral discs, mince, digest with collagenase type II (0.2%) for 4 hours at 37°C, filter through 70µm strainer. Culture in DMEM-HG + 20% FBS + penicillin/streptomycin. Treat with Cartalax (1nM-10µM) under hypoxic conditions (5% O2, mimicking the avascular disc environment) for 72 hours. Measure aggrecan and type II collagen expression. Compare with Epithalon (Ala-Glu-Asp-Gly) in parallel NP cell cultures at matched molar concentrations to characterise whether Cartalax's connective tissue bioregulator activity extends to NP cells or is chondrocyte-specific.

Cartalax and Bioregulator Combination Research

The tissue-specific bioregulator hypothesis suggests that combining Cartalax (cartilage) with other Khavinson bioregulators targeting different tissues could produce complementary effects in musculoskeletal ageing research. Relevant combinations include Cartalax with Epithalon (pineal, antioxidant and circadian restoration), Cartalax with Thymalin (thymus, immune modulation), and Cartalax with Vilon (thymus, dipeptide immunomodulator).

For factorial combination research: use aged rat chondrocytes (isolated from 18-24 month animals, which show reduced COL2A1 and aggrecan expression compared to young adult chondrocytes) in a 2×2 factorial design with Cartalax and Epithalon as the two independent variables. Four treatment groups: vehicle, Cartalax alone (10nM), Epithalon alone (10nM), Cartalax + Epithalon (10nM each). Measure COL2A1, ACAN, MMP-13, and ADAMTS-5 by RT-PCR at 48 hours, and type II collagen protein by Western blot. If the Cartalax + Epithalon combination produces greater COL2A1 restoration than either compound alone (additive or synergistic response), this supports the multi-tissue bioregulator strategy for comprehensive musculoskeletal ageing research. If effects are identical to the most active single compound, the pathways converge — a mechanistically informative finding about the shared versus independent signalling of these two Ala-Glu-Asp-containing bioregulators.

Cartalax and Proteoglycan Biology

The proteoglycan aggrecan is the primary load-bearing macromolecule in articular cartilage — its highly sulfated chondroitin and keratan sulphate glycosaminoglycan chains attract water through Donnan osmotic pressure, providing the compressive stiffness that allows cartilage to resist joint loading. Aggrecan loss is the first measurable molecular event in osteoarthritis, preceding type II collagen loss and structural cartilage breakdown by years. Cartalax effects on aggrecan synthesis therefore represent a mechanistically important early-stage OA research target.

For aggrecan research with Cartalax: measure aggrecan synthesis at multiple levels. Aggrecan core protein by Western blot (using anti-aggrecan core protein antibody) provides protein synthesis data. Glycosaminoglycan content by DMMB (dimethylmethylene blue) colorimetric assay quantifies total proteoglycan chains. Aggrecan gene expression by RT-PCR targeting the ACAN transcript provides mRNA-level data. For the most physiologically relevant measurement, use the alcian blue or safranin-O histochemical staining on fixed chondrocyte monolayers or pellet cultures — these dyes directly stain sulfated glycosaminoglycans in situ, showing distribution as well as total content.

Importantly, aggrecan catabolism by ADAMTS aggrecanases (primarily ADAMTS-4 and ADAMTS-5) produces characteristic neoepitopes (ARGSVIL..., NITEGE...) that can be measured by neoepitope-specific antibodies in conditioned medium. These neoepitopes directly quantify aggrecanase-mediated aggrecan degradation — a distinct endpoint from total aggrecan content or synthesis. Cartalax effects on ADAMTS-generated aggrecan neoepitopes alongside aggrecan synthesis data provide a complete picture of aggrecan turnover balance in treated chondrocyte cultures.

Cartalax and Subchondral Bone Research

Osteoarthritis is a whole-joint disease — cartilage degradation occurs alongside subchondral bone remodelling, synovial inflammation, and periarticular muscle atrophy. Subchondral bone thickening and sclerosis in OA alters the mechanical environment of overlying cartilage, and subchondral osteoblast-secreted factors (including TGF-beta, IGF-1, and WNT ligands) produce paracrine signals that affect chondrocyte biology.

For subchondral bone research relevant to Cartalax: use a co-culture model pairing primary chondrocytes with subchondral osteoblasts separated by a transwell membrane (0.4µm pore, allowing soluble factor exchange without direct cell contact). Apply Cartalax (1-100nM) to the co-culture system and measure changes in both cell populations: chondrocyte gene expression (COL2A1, ACAN, MMP-13) and osteoblast gene expression (RUNX2, OCN, RANKL/OPG ratio) simultaneously. If Cartalax modulates the paracrine crosstalk between chondrocytes and osteoblasts — not just direct chondrocyte effects — this positions it within the broader joint biology research framework beyond isolated chondrocyte pharmacology.